title: Chondroitin for osteoarthritis.
abstract: BACKGROUND
  Osteoarthritis, a common joint disorder, is one of the leading causes of disability. Chondroitin has emerged as a new treatment. Previous meta-analyses have shown contradictory results on the efficacy of chondroitin. This, in addition to the publication of more trials, necessitates a systematic review.
  
  
  OBJECTIVE
  To evaluate the benefit and harm of oral chondroitin for treating osteoarthritis compared with placebo or a comparator oral medication including, but not limited to, nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, opioids, and glucosamine or other "herbal" medications.
  
  
  METHODS
  We searched seven databases up to November 2013, including the Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE, CINAHL, EMBASE, Science Citation Index (Web of Science) and Current Controlled Trials. We searched the US Food and Drug Administration (FDA) and European Medicines Agency (EMEA) websites for adverse effects. Trial registers were not searched.
  
  
  METHODS
  All randomized or quasi-randomized clinical trials lasting longer than two weeks, studying adults with osteoarthritis in any joint, and comparing chondroitin with placebo, an active control such as NSAIDs, or other "herbal" supplements such as glucosamine.
  
  
  METHODS
  Two review authors independently performed all title assessments, data extractions, and risk of bias assessments.
  
  
  RESULTS
  Forty-three randomized controlled trials including 4,962 participants treated with chondroitin and 4,148 participants given placebo or another control were included. The majority of trials were in knee OA, with few in hip and hand OA. Trial duration varied from 1 month to 3 years. Participants treated with chondroitin achieved statistically significantly and clinically meaningful better pain scores (0-100) in studies less than 6 months than those given placebo with an absolute risk difference of 10% lower (95% confidence interval (CI), 15% to 6% lower; number needed to treat (NNT) = 5 (95% CI, 3 to 8; n = 8 trials) (level of evidence, low; risk of bias, high); but there was high heterogeneity between the trials (T(2) = 0.07; I(2) = 70%, which was not easily explained by differences in risk of bias or study sample size). In studies longer than 6 months, the absolute risk difference for pain was 9% lower (95% CI 18% lower to 0%); n = 6 trials; T(2) = 0.18; I(2) = 83% ), again with low level of evidence.For the Western Ontario and McMaster Universities Osteoarthritis Index Minimal Clinically Important Improvement (WOMAC MCII Pain subscale) outcome, a reduction in knee pain by 20% was achieved by 53/100 in the chondroitin group versus 47/100 in the placebo group, an absolute risk difference of 6% (95% CI 1% to 11%), (RR 1.12, 95% CI 1.01 to 1.24; T(2) = 0.00; I(2) = 0%) (n = 2 trials, 1253 participants; level of evidence, high; risk of bias, low).Differences in Lequesne's index (composite of pain,function and disability) statistically significantly favoured chondroitin as compared with placebo in studies under six months, with an absolute risk difference of 8% lower (95% CI 12% to 5% lower; T(2)= 0.78; n = 7 trials) (level of evidence, moderate; risk of bias, unclear), also clinically meaningful. Loss of minimum joint space width in the chondroitin group was statistically significantly less than in the placebo group, with a relative risk difference of 4.7% less (95% CI 1.6% to 7.8% less; n = 2 trials) (level of evidence, high; risk of bias, low). Chondroitin was associated with statistically significantly lower odds of serious adverse events compared with placebo with Peto odds ratio of 0.40 (95% CI 0.19 to 0.82; n = 6 trials) (level of evidence, moderate). Chondroitin did not result in statistically significant numbers of adverse events or withdrawals due to adverse events compared with placebo or another drug. Adverse events were reported in a limited fashion, with some studies providing data and others not.Comparisons of chondroitin taken alone or in combination with glucosamine or another supplement showed a statistically significant reduction in pain (0-100) when compared with placebo or an active control, with an absolute risk difference of 10% lower (95% CI 14% to 5% lower); NNT = 4 (95% CI 3 to 6); T(2) = 0.33; I(2) = 91%; n = 17 trials) (level of evidence, low). For physical function, chondroitin in combination with glucosamine or another supplement showed no statistically significant difference from placebo or an active control, with an absolute risk difference of 1% lower (95% CI 6% lower to 3% higher with T(2) = 0.04; n = 5 trials) (level of evidence, moderate). Differences in Lequesne's index statistically significantly favoured chondroitin as compared with placebo, with an absolute risk difference of 8% lower (95% CI, 12% to 4% lower; T(2) = 0.12; n = 10 trials) (level of evidence, moderate). Chondroitin in combination with glucosamine did not result in statistically significant differences in the numbers of adverse events, withdrawals due to adverse events, or in the numbers of serious adverse events compared with placebo or with an active control.The beneficial effects of chondroitin in pain and Lequesne's index persisted when evidence was limited to studies with adequate blinding or studies that used appropriate intention to treat (ITT) analyses. These beneficial effects were uncertain when we limited data to studies with appropriate allocation concealment or a large study sample (> 200) or to studies without pharmaceutical funding.
  
  
  CONCLUSIONS
  A review of randomized trials of mostly low quality reveals that chondroitin (alone or in combination with glucosamine) was better than placebo in improving pain in participants with osteoarthritis in short-term studies. The benefit was small to moderate with an 8 point greater improvement in pain (range 0 to 100) and a 2 point greater improvement in Lequesne's index (range 0 to 24), both seeming clinically meaningful. These differences persisted in some sensitivity analyses and not others. Chondroitin had a lower risk of serious adverse events compared with control. More high-quality studies are needed to explore the role of chondroitin in the treatment of osteoarthritis. The combination of some efficacy and low risk associated with chondroitin may explain its popularity among patients as an over-the-counter supplement.
authors: Department of Medicine, Birmingham VA Medical Center, Faculty Office Tower 805B, 510 20th Street South, Birmingham, AL, USA, 35294.
authors: Jasvinder A
authors: JA
authors: Singh
authors: Shahrzad
authors: S
authors: Noorbaloochi
authors: Roderick
authors: R
authors: MacDonald
authors: Lara J
authors: LJ
authors: Maxwell
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D002809:Chondroitin Sulfates / Q000627:therapeutic use*; D005944:Glucosamine / Q000627:therapeutic use; D006225:Hand; D006801:Humans; D010003:Osteoarthritis / Q000188:drug therapy*; D015207:Osteoarthritis, Hip / Q000188:drug therapy; D020370:Osteoarthritis, Knee / Q000188:drug therapy; D010147:Pain Measurement; D016032:Randomized Controlled Trials as Topic
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D002809:Chondroitin Sulfates; D005944:Glucosamine
references: Rheum Dis Clin North Am. 1999 May;25(2):379-95
references: 10356424
references: Clin Rheumatol. 2002 Jun;21(3):231-43
references: 12111630
references: J Bone Miner Metab. 2002;20(5):298-302
references: 12203036
references: J Fam Pract. 2003 Dec;52(12):919-20
references: 14653970
references: Arch Intern Med. 2002 Oct 14;162(18):2113-23
references: 12374520
references: Arch Intern Med. 2003 Jul 14;163(13):1587-90
references: 12860582
references: Rev Rhum Engl Ed. 1995 Jun;62(6 Suppl 1):33S-41S
references: 7583181
references: Br J Anaesth. 2008 Jul;101(1):17-24
references: 18487245
references: Osteoarthritis Cartilage. 2010 Jun;18 Suppl 1:S32-40
references: 20399899
references: N Engl J Med. 2006 Feb 23;354(8):795-808
references: 16495392
references: Ann Rheum Dis. 2010 Aug;69(8):1459-64
references: 20525840
references: Drugs Aging. 2005;22(2):141-61
references: 15733021
references: Osteoarthritis Cartilage. 2000 Nov;8(6):395-403
references: 11069723
references: Osteoarthritis Cartilage. 2000 Sep;8(5):343-50
references: 10966840
references: Osteoarthritis Cartilage. 2013 Jan;21(1):22-7
references: 23059756
references: Drugs Aging. 2003;20(7):517-26
references: 12749749
references: Semin Arthritis Rheum. 1990 Dec;20(3 Suppl 1):42-50
references: 2287948
references: Psychol Bull. 1992 Jul;112(1):155-9
references: 19565683
references: Arthritis Rheum. 2011 Nov;63(11):3383-91
references: 21898340
references: Cranio. 2001 Apr;19(2):130-9
references: 11842864
references: Open Rheumatol J. 2013;7:1-12
references: 23493263
references: Cochrane Database Syst Rev. 2008 Oct 08;(4):CD004376
references: 18843657
references: Rheumatol Int. 2010 Jan;30(3):357-63
references: 19544061
references: Epidemiol Rev. 1988;10:1-28
references: 3066625
references: Arthritis Rheum. 2007 Feb;56(2):555-67
references: 17265490
references: Presse Med. 2000 Sep;29(27 Suppl):19-20
references: 11045133
references: Ann Rheum Dis. 2000 Dec;59(12):936-44
references: 11087696
references: Can Fam Physician. 2001 Feb;47:275-7
references: 11228027
references: J Rheumatol. 1997 Apr;24(4):779-81
references: 9101517
references: J Rheumatol Suppl. 1995 Feb;43:23-5
references: 7752127
references: J Rheumatol. 2003 Apr;30(4):886-90
references: 12672223
references: Osteoarthritis Cartilage. 2008;16 Suppl 3:S22-4
references: 18768335
references: Ann Emerg Med. 1996 Apr;27(4):439-41
references: 8604855
references: Exp Ther Med. 2011 Sep;2(5):893-899
references: 22977594
references: Osteoarthritis Cartilage. 1994 Mar;2(1):51-9
references: 11548224
references: J Rheumatol. 1996 Aug;23(8):1385-91
references: 8856618
references: Osteoarthritis Cartilage. 1998 May;6 Suppl A:25-30
references: 9743816
references: Ann Rheum Dis. 1989 Apr;48(4):271-80
references: 2712610
references: Osteoarthritis Cartilage. 2007 Nov;15(11):1256-66
references: 17561418
references: Rev Rhum Mal Osteoartic. 1992 Jul-Sep;59(7-8):466-72
references: 1485136
references: BMJ. 2010 Sep 16;341:c4675
references: 20847017
references: Int J Tissue React. 2002;24(1):29-32
references: 12013151
references: Emerg Med J. 2001 May;18(3):205-7
references: 11354213
references: Rheumatology (Oxford). 2007 Nov;46(11):1652-6
references: 17855425
references: Presse Med. 1998 Feb 7;27(5):211-4
references: 9768015
references: Ter Arkh. 2003;75(9):82-6
references: 14582441
references: Osteoarthritis Cartilage. 1998 May;6 Suppl A:39-46
references: 9743819
references: Osteoarthritis Cartilage. 2003 Mar;11(3):228-30
references: 12623294
references: J Rheumatol. 2001 Jan;28(1):173-81
references: 11196521
references: Osteoarthritis Cartilage. 2004 May;12(5):389-99
references: 15094138
references: Ter Arkh. 2000;72(10):71-2
references: 11220884
references: J Fam Pract. 2003 Mar;52(3):237-9
references: 12620182
references: Rom J Morphol Embryol. 1994 Jul-Dec;40(3-4):119-23
references: 7548883
references: Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004257
references: 16437479
references: Instr Course Lect. 2000;49:491-4
references: 10829202
references: Arthritis Rheum. 2009 Feb;60(2):524-33
references: 19180484
references: Acad Emerg Med. 1998 Nov;5(11):1086-90
references: 9835471
references: J Rheumatol. 2003 Mar;30(3):523-8
references: 12610812
references: Arthritis Rheum. 2008 Oct;58(10 ):3183-91
references: 18821708
references: Ann Intern Med. 2007 Apr 17;146(8):580-90
references: 17438317
references: Ter Arkh. 1999;71(5):51-3
references: 10399232
references: Osteoarthritis Cartilage. 1998 May;6 Suppl A:37-8
references: 9743818
references: Ter Arkh. 1992;64(5):59-60
references: 1455377
references: Am J Health Syst Pharm. 2000 May 1;57(9):842
references: 10840521
references: Osteoarthritis Cartilage. 2004 Apr;12 (4):269-76
references: 15023378
references: J Pain. 2008 Feb;9(2):105-21
references: 18055266
references: J Rheumatol. 2000 Jan;27(1):205-11
references: 10648040
references: Osteoarthritis Cartilage. 1998 May;6 Suppl A:31-6
references: 9743817
references: Drugs Exp Clin Res. 1991;17(1):53-7
references: 1914837
references: Ann Rheum Dis. 2005 Jan;64(1):29-33
references: 15208174
references: Ann Rheum Dis. 2007 May;66(5):639-45
references: 17204566
references: Cochrane Database Syst Rev. 2006 Jul 19;(3):CD005522
references: 16856101
references: Osteoarthritis Cartilage. 2010 Jun;18 Suppl 1:S28-31
references: 20399895
references: Arthritis Rheum. 2005 Mar;52(3):779-86
references: 15751094
references: Presse Med. 1998 Nov 21;27(36):1862-5
references: 9856136
references: JAMA. 2000 Mar 15;283(11):1469-75
references: 10732937
references: Arch Intern Med. 2003 Jul 14;163(13):1514-22
references: 12860572
references: J Sci Food Agric. 2012 Mar 15;92(4):862-9
references: 21969261
references: Cochrane Database Syst Rev. 2005 Apr 18;(2):CD002946
references: 15846645
references: J Rheumatol. 1988 Dec;15(12):1833-40
references: 3068365
references: Clin Rheumatol. 2012 Sep;31(9):1347-57
references: 22729470
references: Arthritis Care Res (Hoboken). 2012 Apr;64(4):465-74
references: 22563589
references: Osteoarthritis Cartilage. 2002 Nov;10(11):836-7
references: 12435326
references: Cochrane Database Syst Rev. 2006 Apr 19;(2):CD005321
references: 16625635
references: Osteoarthritis Cartilage. 2012 Jan;20(1):22-8
references: 22033041
references: Drugs Exp Clin Res. 1991;17(1):45-51
references: 1914836
references: Pain. 2011 Oct;152(10):2399-404
references: 21856077
references: Ter Arkh. 2005;77(11):69-75
references: 16404866
references: Mil Med. 1999 Feb;164(2):85-91
references: 10050562
references: Osteoarthritis Cartilage. 2001 Jan;9(1):14-21
references: 11178943
references: Arthritis Rheum. 2000 Sep;43(9):1905-15
references: 11014340
references: Drugs Exp Clin Res. 2004;30(1):11-6
references: 15134386
references: Am J Med. 2004 Nov 1;117(9):643-9
references: 15501201
references: Schweiz Med Wochenschr. 1968 Jun 15;98(24):904-7
references: 4886076
references: Ann Intern Med. 2008 Feb 19;148(4):268-77
references: 18283204
references: Scand J Rheumatol. 1987;16(5):377-80
references: 3120308
references: Biosci Biotechnol Biochem. 2009 Feb;73(2):288-92
references: 19202302
references: Clin J Pain. 2000 Jun;16(2 Suppl):S106-12
references: 10870749
references: Pain. 2001 Nov;94(2):149-58
references: 11690728
references: Ann Rheum Dis. 2011 Jun;70(6):982-9
references: 21367761
references: Clin Rheumatol. 2010 Jun;29(6):659-70
references: 20179981
references: Osteoarthritis Cartilage. 2007 Mar;15(3):273-80
references: 17052924
references: Ter Arkh. 2001;73(11):84-7
references: 11806217
references: Br J Hosp Med (Lond). 2006 Jun;67(6):290-3
references: 16821730
references: Cochrane Database Syst Rev. 2008 Jan 23;(1):CD005118
references: 18254069
references: Consum Rep. 2002 Jan;67(1):18-21
references: 11771558
references: J Int Soc Sports Nutr. 2011 Jun 20;8(1):8
references: 21689421
references: Cartilage. 2013 Jul;4(3):219-26
references: 26069668
references: Rheumatology (Oxford). 2002 Feb;41(2):148-52
references: 11886962
references: Arthritis Rheum. 1990 Nov;33(11):1601-10
references: 2242058